T cell Dissimilarities in B Cell Activating Factor-Deficient Versus B Cell Activating Factor Receptor 3-Deficient Systemic Lupus Erythematosus-Prone NZM 2328 Mice as Contributors to Their Divergent Clinical Outcomes.
Journal
ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025
Informations de publication
Date de publication:
14 Aug 2024
14 Aug 2024
Historique:
revised:
29
05
2024
received:
12
03
2024
accepted:
08
06
2024
medline:
15
8
2024
pubmed:
15
8
2024
entrez:
14
8
2024
Statut:
aheadofprint
Résumé
We assessed the contributions of B cell and T cell subsets to the disparate clinical outcomes in NZM.Baff We assessed in NZM wild-type, NZM.Baff In each age and sex cohort, percentages and numbers of CD19 Differences between NZM.Baff
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Références
Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL‐lpr/lpr mice. J Immunol 1998;160(1):51–59.
Jacob N, Guo S, Mathian A, et al. B Cell and BAFF dependence of IFN‐α‐exaggerated disease in systemic lupus erythematosus‐prone NZM 2328 mice. J Immunol 2011;186(8):4984–4993.
Ramanujam M, Wang X, Huang W, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor‐Ig in murine systemic lupus erythematosus. J Immunol 2004;173(5):3524–3534.
Marinov AD, Wang H, Bastacky SI, et al. The type II anti‐CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine lupus model. Arthritis Rheumatol 2021;73(5):826–836.
Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo‐controlled, phase 3 trial. Lancet 2011;377(9767):721–731.
Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo‐controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63(12):3918–3930.
Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty‐two‐week randomized, double‐blind, placebo‐controlled study. Arthritis Rheumatol 2017;69(5):1016–1027.
Zhang F, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo‐controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 2018;77(3):355–363.
Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19‐targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 2019;11(482):eaav1648.
Mackensen A, Müller F, Mougiakakos D, et al. Anti‐CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022;28(10):2124–2132.
Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285(5425):260–263.
Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189(11):1747–1756.
Thompson JS, Schneider P, Kalled SL, et al. BAFF binds to the tumor necrosis factor receptor‐like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 2000;192(1):129–135.
Do RKG, Hatada E, Lee H, et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000;192(7):953–964.
Batten M, Groom J, Cachero TG, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000;192(10):1453–1466.
Gross JA, Dillon SR, Mudri S, et al. TACI‐Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001;15(2):289–302.
Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA‐independent pathway. Science 2001;293(5537):2111–2114.
Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190(11):1697–1710.
Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B‐cell autoimmune disease. Nature 2000;404(6781):995–999.
Laabi Y, Gras MP, Brouet JC, et al. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res 1994;22(7):1147–1154.
vonBülow GU, Bram RJ. NF‐AT activation induced by a CAML‐interacting member of the tumor necrosis factor receptor superfamily. Science 1997;278(5335):138–141.
Thompson JS, Bixler SA, Qian F, et al. BAFF‐R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293(5537):2108–2111.
Yan M, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 2001;11(19):1547–1552.
Harless SM, Lentz VM, Sah AP, et al. Competition for BLyS‐mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol. 2001;11(24):1986–1989.
Sasaki Y, Casola S, Kutok JL, et al. TNF family member B cell‐activating factor (BAFF) receptor‐dependent and ‐independent roles for BAFF in B cell physiology. J Immunol. 2004;173(4):2245–2252.
Shulga‐Morskaya S, Dobles M, Walsh ME, et al. B cell‐activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell‐independent antibody formation. J Immunol 2004;173(4):2331–2341.
Xu S, Lam KP. B‐cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001;21(12):4067–4074.
vonBülow GU, vanDeursen JM, Bram RJ. Regulation of the T‐independent humoral response by TACI. Immunity 2001;14(5):573–582.
Yan M, Wang H, Chan B, et al. Activation and accumulation of B cells in TACI‐deficient mice. Nat Immunol. 2001;2(7):638–643.
Jacob CO, Pricop L, Putterman C, et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus‐prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol. 2006;177(4):2671–2680.
Jacob CO, Yu N, Guo S, et al. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis Rheum 2013;65(4):1043–1054.
Stohl W, Yu N, Wu Y. B cell and T cell dissimilarities in BAFF‐deficient versus BR3‐deficient C57BL/6 mice. J Immunol 2022;209(11):2133–2140.
Jacob CO, Guo S, Jacob N, et al. Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum 2012;64(5):1610–1619.
Wofsy D, Seaman WE. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med 1985;161(2):378–391.
Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol 1987;138(10):3247–3253.
Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299(5609):1057–1061.
Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330–336.
Khattri R, Cox T, Yasayko SA, et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003;4(4):337–342.
Komatsu N, Okamoto K, Sawa S, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 2014;20(1):62–68.
Collins CE, Dall'Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24‐month results from the OBSErve study in the USA. Lupus Sci Med 2016;3(1):e000118.
Schwarting A, Schroeder JO, Alexander T, et al. First real‐world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: results from the OBSErve Germany Study. Rheumatol Ther 2016;3(2):271–290.
Touma Z, Sayani A, Pineau CA, et al. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study. Rheumatol Int 2017;37(6):865–873.
Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate‐to‐severe systemic lupus erythematosus (SLE): 52‐week data (APRIL‐SLE randomised trial). Ann Rheum Dis 2015;74(11):2006–2015.
Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE‐1, a 52‐week, phase III, multicentre, randomised, double‐blind, placebo‐controlled study. Ann Rheum Dis 2016;75(2):323–331.
Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B‐cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double‐blind, placebo‐controlled trial. Ann Rheum Dis 2018;77(6):883–889.
Wu D, Li J, Xu D, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double‐blind, placebo‐controlled trial. Ann Rheum Dis 2024;83(4):475–487.
Dhillon S. Telitacicept: first approval. Drugs. 2021;81(14):1671–1675.
Sun L, Shen Q, Gong Y, et al. Safety and efficacy of telitacicept in refractory childhood‐onset systemic lupus erythematosus: a self‐controlled before‐after trial. Lupus 2022;31(8):998–1006.
Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64(7):2328–2337.
Merrill JT, vanVollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B‐cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE‐2, a 52‐week, phase III, multicentre, randomised, double‐blind, placebo‐controlled study. Ann Rheum Dis 2016;75(2):332–340.
Mayne CG, Amanna IJ, Nashold FE, et al. Systemic autoimmunity in BAFF‐R‐mutant A/WySnJ strain mice. Eur J Immunol 2008;38(2):587–598.
Hao Y, O'Neill P, Naradikian MS, et al. A B‐cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood. 2011;118(5):1294–1304.
Rubtsov AV, Rubtsova K, Fischer A, et al. Toll‐like receptor 7 (TLR7)‐driven accumulation of a novel CD11c+ B‐cell population is important for the development of autoimmunity. Blood 2011;118(5):1305–1315.
Sutherland APR, Ng LG, Fletcher CA, et al. BAFF augments certain Th1‐associated inflammatory responses. J Immunol 2005;174(9):5537–5544.
Walters S, Webster KE, Sutherland A, et al. Increased CD4+Foxp3+ T cells in BAFF‐transgenic mice suppress T cell effector responses. J Immunol 2009;182(2):793–801.
Stohl W, Yu N. Promotion of T regulatory cells in mice by B cells and BAFF. J Immunol 2020;204(9):2416–2428.
Marsters SA, Yan M, Pitti RM, et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000;10(13):785–788.
Yu G, Boone T, Delaney J, et al. APRIL and TALL‐I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000;1(3):252–256.
Wu Y, Bressette D, Carrell JA, et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000;275(45):35478–35485.
Rennert P, Schneider P, Cachero TG, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 2000;192(11):1677–1684.
Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA‐4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA‐4. Immunity. 1995;3(5):541–547.
Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla‐4. Science 1995;270(5238):985–988.
Stohl W, Yu N, Wu Y. Preferential expansion of Foxp3+ T regulatory cells in CTLA‐4‐deficient and CTLA‐4‐haploinsufficient C57BL/6 mice. Immunohorizons 2022;6(7):507–514.
McCormick N, Yokose C, Challener GJ, et al. Serum urate and recurrent gout. JAMA 2024;331(5):417–424.
Jacob CO, Yu N, Sindhava V, et al. Differential development of systemic lupus erythematosus in NZM 2328 mice deficient in discrete pairs of BAFF receptors. Arthritis Rheumatol 2015;67(9):2523–2535.
Cambridge G, Isenberg DA, Edwards JCW, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008;67(7):1011–1016.
Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti‐double‐stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2013;65(10):2672–2679.
Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: the randomized, double‐blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62(1):222–233.
Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64(4):1215–1226.
Bowman SJ, Fox R, Dörner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double‐blind, placebo‐controlled, phase 2b dose‐finding trial. Lancet 2022;399(10320):161–171.
Huard B, Schneider P, Mauri D, et al. T cell costimulation by the TNF ligand BAFF. J Immunol. 2001;167(11):6225–6231.